Navigation Links
Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009
Date:8/5/2009

NANJING, China, Aug. 5 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group (NYSE: SCR), a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in China, announced today that it intends to release its 2009 second quarter results on Monday, August 17, 2009, after the market closes in the United States. Simcere's chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company's 2009 second quarter results on Tuesday, August 18, at 8 a.m. ET (Tuesday, August 18, at 8 p.m. Beijing/Hong Kong time).

    To access the conference call, please dial:

    United States toll-free:   +1.866.510.0705
    International:             +1.617.597.5363
    North China toll-free:     10.800.152.1490
    South China toll-free:     10.800.130.0399
    China toll free / Netcom:  10 800 852 1490
    Hong Kong:                 +852.3002.1672

Please ask to be connected to Q2 2009 Simcere Pharmaceutical Group Earnings Conference Call and provide the following passcode: 78992895.

Simcere will also broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the "Investor Relations" section of the company's web site at http://www.simcere.com .


    Following the earnings conference call, an archive of the call will be
available by dialing:

    United States toll-free:     +1.888.286.8010
    International:               +1.617.801.6888

The passcode for replay participants is: 77592594. The telephone replay also will be archived on the "Investor Relations" section of the company's web site for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR, Simcere) is a leading manufacturer and supplier of branded generic and innovative pharmaceuticals in China. In recent years, Simcere has been focusing its strategy on the development of innovative pharmaceuticals and first-to-market generics, and has introduced an innovative anti-cancer medication Endu, a first-to-market medication Sinofuan, and first-to-market generics such as Bicun and Anxin. Simcere manufactures and sells antibiotics, anti-cancer medication and stroke management medication. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .


'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
2. Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir
3. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
4. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
5. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
6. Simcere Pharmaceutical Group Acquires 70% Stake in Wuhu Zhong Ren Pharmaceutical Co. Ltd.
7. Simcere Pharmaceutical Group to Announce First Quarter 2008 Earnings on Tuesday, May 6, 2008
8. Simcere Pharmaceutical Group Announces Participation in Brean Murray Carret & Co.s Fourth Investor Tour of China
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. Simcere Pharmaceutical Group to Announce Fourth Quarter 2007 Earnings on Tuesday, March 4, 2008
11. Simcere Pharmaceutical Group Reports Third Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)... ... January 17, 2017 , ... Recently, patients and staff from A ... other volunteers and organizations in support of the annual Binder Park Zoo Halloween celebration ... up in colorful costumes of all designs coming out to enjoy games, face painting, ...
(Date:1/16/2017)... ... ... Anybody who may be looking for a substance abuse rehabilitation program with ... a holistic treatment center for addiction located in Marne, MI. This video, which can ... and staff that visited the 2016 Recovery Palooza support event in nearby Grand Rapids. ...
(Date:1/16/2017)... ... January 16, 2017 , ... Atlanta-based incentive company ... in the wheelchair accessibility industry, BraunAbility . Incentive Solutions will provide BraunAbility ... accessible vehicles. With this new incentive plan, BraunAbility plans to continue their tradition ...
(Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... One thing ... only to treat, but to test for, as well. The money spent screening for ... year.(1) Doctors in the U.S. screen patients for cancer more than in any other ...
(Date:1/15/2017)... ... 15, 2017 , ... Going above and beyond the practical ... better communities around the world by offering the Gensuite team and their services ... team members to become involved in a cause that is bigger than themselves ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... TORONTO , Jan. 16, 2017 When synthetic ... to market their product as top-rate. They offered free samples, ... top-notch customer service. Soon, business was booming. ... often described as 100 times more powerful than morphine, has ... in last 2 years. One dealer,s recorded fentanyl ...
(Date:1/16/2017)... PUNE, India , January 16, 2017 /PRNewswire/ ... Research, titled, "Vital Signs Monitoring Devices Market by Type and ... that the global vital signs monitoring devices market size was ... $5,491 million by 2022, growing at a CAGR of 5.8% ... was the leading regional market in global vital signs monitoring ...
(Date:1/16/2017)... PUNE, India , January 16, 2017 ... & Its Derivatives Market by Product Type (Methyl, ... Personal Care, Foods & Beverages, Surface Coatings ... 2021", published by MarketsandMarkets, the market was ... and is projected to reach USD 6.41 ...
Breaking Medicine Technology: